Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02242981 · ClinicalTrials.gov registry record · Phase 1
A Study of How the Body Breaks Down and Eliminates LY2623091
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT02242981: Completed Phase 1 study, sponsored by Eli Lilly and Company.
NCT02242981 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02242981, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This type of study is called a radiolabeled study. For this study, LY2623091 (study drug) has been specially prepared to contain radiolabeled carbon \[\^14C\]. \[\^14C\] is a naturally occurring radioactive form of the element, carbon. This study will increase understanding about how the drug appears in the blood, urine, and stool after it is administered to healthy participants. Information about any side effects that may occur will also be collected. This study will last up to 22 days for each participant, not including screening. Screening is required within 28 days prior to enrollment
Primary Outcome
Cumulative percent of radioactive dose recovered in urine and feces after administration at specified intervals.
Interventions
- DRUG LY2623091
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2014-09 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
What the finished NCT02242981 record still lists
NCT02242981 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which LY2623091 is the first listed.
NCT02242981 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02242981 about?
NCT02242981 is a clinical study titled "A Study of How the Body Breaks Down and Eliminates LY2623091". This type of study is called a radiolabeled study. For this study, LY2623091 (study drug) has been specially prepared to contain radiolabeled carbon \[\^14C\]. \[\^14C\] is a naturally occurring radioactive form of the element, carbon. This study will increase understanding about how the drug appear...
What is the current status of trial NCT02242981?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2014-09. Estimated completion is 2014-11.
What interventions are being tested in trial NCT02242981?
The interventions under investigation include: LY2623091 (DRUG).
Who is sponsoring clinical trial NCT02242981?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02242981's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia